Natera, Inc. $NTRA Stock Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA raised its position in shares of Natera, Inc. (NASDAQ:NTRA) by 9.9% during the 3rd quarter, Holdings Channel reports. The firm owned 55,946 shares of the medical research company’s stock after buying an additional 5,022 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Natera were worth $23,123,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. SYM FINANCIAL Corp raised its stake in shares of Natera by 1.7% in the third quarter. SYM FINANCIAL Corp now owns 1,897 shares of the medical research company’s stock worth $784,000 after purchasing an additional 32 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Natera by 4.6% during the third quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock worth $337,000 after purchasing an additional 36 shares during the period. AlphaCentric Advisors LLC boosted its position in Natera by 3.0% in the third quarter. AlphaCentric Advisors LLC now owns 1,432 shares of the medical research company’s stock valued at $592,000 after buying an additional 42 shares during the last quarter. VestGen Advisors LLC boosted its position in Natera by 3.1% in the third quarter. VestGen Advisors LLC now owns 1,460 shares of the medical research company’s stock valued at $603,000 after buying an additional 44 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after buying an additional 47 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Trading Up 2.5%

NASDAQ NTRA opened at $319.82 on Thursday. The stock has a 50-day simple moving average of $379.91 and a two-hundred day simple moving average of $270.81. Natera, Inc. has a fifty-two week low of $181.00 and a fifty-two week high of $437.41.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14). Natera had a negative return on equity of 8.61% and a negative net margin of 5.66%. The company had revenue of $793.98 million during the quarter, compared to analysts’ expectations of $707.54 million. During the same quarter in the previous year, the company earned ($0.64) EPS. The firm’s quarterly revenue was up 34.1% compared to the same quarter last year. On average, research analysts anticipate that Natera, Inc. will post -1.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NTRA. Citigroup increased their price target on shares of Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Piper Sandler restated an “overweight” rating and set a $363.50 price objective on shares of Natera in a research note on Friday, November 6th. Wells Fargo & Company upped their price objective on shares of Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Morgan Stanley increased their price objective on shares of Natera from $355.00 to $435.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Finally, Guggenheim increased their price objective on shares of Natera from $360.00 to $475.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and an average price target of $394.31.

Insider Activity at Natera

In other Natera news, CEO Steven Chapman sold 3,801 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $411.80, for a total value of $1,565,251.80. Following the sale, the chief executive officer owned 87,431 shares in the company, valued at approximately $36,004,085.80. This represents a 4.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 1,906 shares of the company’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $425.55, for a total value of $811,098.30. Following the completion of the sale, the chief financial officer owned 46,574 shares in the company, valued at approximately $19,819,565.70. This represents a 3.93% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 47,056 shares of company stock worth $17,760,989. 5.05% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.